I

f it feels like you’ve been hearing from the head of the Food and Drug Administration a lot lately, you’re not imagining it.

It’s a rare day here at STAT when we don’t receive in our inboxes a “Statement from FDA Commissioner Scott Gottlieb, M.D.” — or at least find him prominently quoted in another new FDA press release. Then there are all his blog posts. His speeches. His congressional testimony. And, of course, his tweets.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Now that you’ve gotten mired in Gottlieb word count, please address the content. I’d say, based on STAT News reportage and those of many other outlets, the man has ‘something worthwhile to say.’ On the other hand, maybe I’m only seeing the ‘cream of the crop’?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy